Catalyst Pharmaceuticals to Hold Third Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday...
October 31 2018 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, today announced that it
will release third quarter 2018 financial results after market
close on Wednesday, November 7, 2018. Further, Catalyst
management will host an investment-community conference call
at 8:30 a.m. ET on Thursday, November 8, 2018 to
discuss the financial results and to provide a corporate update.
Investors who wish to participate in the
conference call may do so by dialing (877) 407-8912 for domestic
and Canadian callers or (201) 689-8059 for international callers.
Those interested in listening to the conference call live via the
internet may do so by visiting the Investors page of the company's
website at www.catalystpharma.com and clicking on the
webcast link on the Investors home page.
A webcast replay will be available on the
Catalyst website for 30 days following the call by visiting the
Investor page of the company's website
at www.catalystpharma.com.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating, chronic neuromuscular
and neurological diseases, including Lambert-Eaton myasthenic
syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK
antibody positive myasthenia gravis, spinal muscular atrophy (SMA)
type 3, and infantile spasms. Firdapse® (amifampridine phosphate)
has received Breakthrough Therapy Designation from the U.S. Food
and Drug Administration (FDA) for the treatment of LEMS and Orphan
Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is
the first and only approved drug in Europe for symptomatic
treatment in adults with LEMS.
Catalyst is also developing CPP-115 to treat
refractory infantile spasms. CPP-115 has been granted U.S. Orphan
Drug Designation for the treatment of infantile spasms by the FDA
and has been granted E.U. Orphan Medicinal Product Designation for
the treatment of West syndrome by the European Commission. In
addition, Catalyst is developing a generic version of Sabril®
(vigabatrin).
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2017 and its other
filings with the U.S. Securities and Exchange
Commission (SEC), could adversely affect Catalyst. Copies of
Catalyst's filings with the SEC are available from
the SEC, may be found on Catalyst's website or may be obtained
upon request from Catalyst. Catalyst does not undertake any
obligation to update the information contained herein, which speaks
only as of this date.
Investor Contact
Brian Korb
Solebury Trout
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024